Acadia Pharmaceuticals Announces Executive Leadership Change
Acadia Pharmaceuticals (Nasdaq: ACAD) announced the departure of Elena Ridloff, Chief Financial Officer, effective September 10, 2021, as she transitions to another biopharmaceutical firm.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
“On behalf of all of us at Acadia, I want to thank Elena for her leadership and contributions which played an important role in supporting Acadia’s growth and long-term business strategy, and we wish her well in her future endeavors,” said
“I want to thank my colleagues at Acadia for their partnership in driving growth of the pimavanserin franchise and advancing important therapies in our pipeline,” said
About
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia-pharm.com and follow us on LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005923/en/
Media Contact:
(858) 914-7161
media@acadia-pharm.com
Investor Contact:
(858) 261-2771
ir@acadia-pharm.com
Source: